CHAPEL HILL, N.C. — WomanCare Global is pleased to announce an expansion of their global product portfolio to include Roselle®, a combined oral contraceptive (COC) pill containing 150 micrograms of levonorgestrel and 30 micrograms of ethinylestradiol and Optinor, a progesterone-only emergency contraception pill (ECP) containing 750 micrograms of levonorgestrel.
Both products were developed by ICON in partnership with a trusted generic manufacturer following an extensive in-depth quality and technical assessment process undertaken by qualified experts in 2005. Both formulations are included in the WHO Interagency List of Essential Medicines for Reproductive Health. ICON is the International Planned Parenthood Federation (IPPF) subsidiary responsible for commodity supply to IPPF member associations.
With this acquisition, WomanCare Global has global rights to Roselle® and Optinor® and a partner in making these branded products available to IPPF’s global network of Member Associations located in over 170 countries. WomanCare Global will also market these products to other public and private sector markets around the world using their established global supply chain and logistics network.
“This partnership with WomanCare Global is a significant step forward in expanding access to quality assured generic hormonal contraceptives at competitive prices,” said ICON’s General Manager, David Smith.
“WomanCare Global is excited about this important strategic alliance with a key partner,” said WomanCare Global Chief Operating Officer Saundra Pelletier. “The addition of these 2 new products to our global portfolio will make a significant difference to women around the world who deserve access to high-quality and affordable products. Roselle® and Optinor® will become important options for women.”
About WomanCare Global
WomanCare Global provides access to high-quality, innovative and affordable reproductive healthcare technologies for contraception, fertility and pregnancy management. WomanCare Global’s mission is to expand the availability of these technologies in both public and private sectors via an established global supply chain reaching over 80 countries and growing, with particular focus on under-served markets inAfrica, Asia and Latin America. WomanCare Global is a hybrid business model, combining the best practices of for-profit and not-for-profit entities. WomanCare Global has regulatory and quality departments that assure adherence to regulatory requirements and global quality standards in addition to a comprehensive global sales, marketing, and distribution channel. For more information about WomanCare Global, visit www.womancareglobal.com
Had to do some research on this company-WomanCare Global??? Are they not following research about synthetic hormones and cancer? Do they think they can market more synthetic hormones under “WomanCare Global?” Guess they do. Marketing. It’s all in the name and the ‘spin.’
Saundra Pelletier – Chief Operating Officer
WomanCare Global, LLC is under the leadership of Chief Operating Officer Saundra Pelletier. Ms. Pelletier is an award-winning, results-driven leader and author who is considered an expert on female healthcare from puberty through menopause. She has over 20 years of experience as an international marketing expert, having launched pharmaceutical and cosmeceutical brands worldwide and expanded indications on female healthcare brands in multiple countries. Her therapeutic experience includes working with oral contraceptives, hormone replacement therapy, anti-bacterials, GnRh agonists, IUDs and other medical devices.